Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
In addition, ORI@CPD-Lipo nanoparticles significantly enhanced antitumor efficacy compared with the free ORI, non-targeted ORI@Lipo, and CKAAKN-blocked ORI@CPD-Lipo, which could be attributed to improved drug cellular uptake mediated by ORI@CPD-Lipo nanoparticles and the cytotoxic effects of the released ORI from the nanoparticles
Use a sterile syringe to draw the recommended dosage
Oxidative damage in synovial tissue is associated with in vivo hypoxic status in the arthritic joint
11 , e1005181 (2015)
Currently, common clinical GLP-1RAs include exenatide and exenatide-LAR [34,35,36,37,38,39,40], lixisenatide [41,42,43,44], beinaglutide [45], liraglutide [46,47,48,49,50,51,52,53], semaglutide [54,55,56,57,58], albiglutide [59,60,61], dulaglutide [62,63,64], oral semaglutide [58, 65,66,67], PEG-loxenatide [68] and tirzepatide [68,69,70,71,72,73] (Table 1)
US$ 26.48
US$ 25.97
US$ 24.77
US$ 28.76
US$ 27.34
US$ 26.73
US$ 25.09
US$ 25.71
US$ 20.58
